Open access
Open access
Powered by Google Translator Translator

Onco-hematology

Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations.

23 Sep, 2022 | 13:07h | UTC

Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations – The BMJ

 

Commentary on Twitter

 


NCCN Guideline | Myeloproliferative neoplasms.

15 Sep, 2022 | 13:05h | UTC

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology – National Comprehensive Cancer Network

 


Retrospective cohort study | Tisagenlecleucel (an anti-CD19 CAR T-cell therapy) for relapsed or refractory B-cell acute lymphoblastic leukemia in infants and children younger than 3 years of age at screening.

13 Sep, 2022 | 12:59h | UTC

Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study – The Lancet Haematology

Commentaries:

CD19 CAR T cells for infants and young children – The Lancet Haematology (free registration required)

CAR-T Therapy Effective in Youngest Kids With ALL — Analysis shows safety and outcomes equivalent to those reported in older children – MedPage Today (free registration required)

 

Commentary on Twitter

 


RCT | Busulfan plus Cyclophosphamide is noninferior to total body irradiation plus Cyclophosphamide for adults Acute B Lymphoblastic Leukemia.

11 Sep, 2022 | 22:24h | UTC

Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial – Journal of Clinical Oncology

 


Large study unravels the risk factors for heart failure among childhood cancer survivors.

11 Sep, 2022 | 22:22h | UTC

Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors – Journal of Clinical Oncology

 


RCT | Lenalidomide-dexamethasone vs. observation in high-risk smoldering myeloma after 12 years of median follow-up time.

8 Sep, 2022 | 14:34h | UTC

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study – European Journal of Cancer (link to abstract – $ for full-text)

 


Review | Diagnosis and treatment of myelodysplastic syndromes.

7 Sep, 2022 | 12:33h | UTC

Diagnosis and Treatment of Myelodysplastic Syndromes: A Review – JAMA (free for a limited period)

Audio Clinical Review: Diagnosis and Management of Myelodysplastic Syndromes – JAMA

 


Cohort Study | Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria.

7 Sep, 2022 | 12:29h | UTC

Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter (thread – click for more)

 


Long-term results of a RCT | Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in chronic lymphocytic leukemia.

31 Aug, 2022 | 11:32h | UTC

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial – Blood

Commentary: Ibrutinib Plus Rituximab Yields Superior Survival Vs FCR in CLL, Regardless of IGHV Status – Cancer Network

 


Single-arm phase 2 study | Rituximab, Lenalidomide, and Ibrutinib in patients with newly diagnosed Large B-Cell Lymphoma.

26 Aug, 2022 | 13:05h | UTC

Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Long-term results of a RCT | Lenalidomide plus Rituximab vs. Rituximab-chemotherapy followed by Rituximab maintenance in untreated advanced Follicular Lymphoma.

26 Aug, 2022 | 13:03h | UTC

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma – Journal of Clinical Oncology

Commentaries:

First-Line Lenalidomide/Rituximab vs Rituximab/Chemotherapy With Rituximab Maintenance for Advanced Follicular Lymphoma – The ASCO Post

Lenalidomide Plus Rituximab Represents Acceptable Chemo-Free Alternative for Untreated Advanced Follicular Lymphoma – OncLive

 

Commentary on Twitter

 


M-A | Interventions to reduce infections in patients with hematological malignancies.

15 Aug, 2022 | 11:51h | UTC

Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis – Blood Advances

Commentary: Prophylactic Immunoglobulin, Vaccinations May Reduce Infections in Hematologic Malignancies – AJMC

 


Long-term results of a phase 2 RCT | Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma.

15 Aug, 2022 | 11:46h | UTC

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial – Journal of Clinical Oncology

Original Study: Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma – New England Journal of Medicine

 


RCT | Low-dose Decitabine vs. low-dose Azacitidine in lower-risk myelodysplastic syndromes.

11 Aug, 2022 | 12:04h | UTC

Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS – NEJM Evidence

 

Commentary on Twitter

 


Single-arm phase 2 study | Long-term follow-up of combination of B-Cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma.

9 Aug, 2022 | 12:22h | UTC

Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Durable Response Achieved With CAR-T Combination in Relapsed/Refractory Multiple Myeloma – Hematology Advisor

 

Commentary on Twitter

 


Guideline | Management of antithrombotic treatments in thrombocytopenic patients with cancer.

5 Aug, 2022 | 14:37h | UTC

EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer – HemaSphere

 


Single-arm phase 1b study | Venetoclax Plus Gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia.

1 Aug, 2022 | 11:46h | UTC

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia – Journal of Clinical Oncology

 

Commentary on Twitter

 


RCT | Short vs. extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia.

27 Jul, 2022 | 12:17h | UTC

Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial – The Lancet Haematology (link to abstract – $ for full-text)

Commentary: Short-Course or Extended Antibiotics in Febrile Neutropenia? – Medscape (free registration required)

 

Commentary on Twitter

 


Cohort Study | Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors.

27 Jul, 2022 | 11:53h | UTC

Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors – Cancer

Commentaries:

People with early-stage Hodgkin lymphoma face a higher risk of dying from cardiovascular disease than from cancer – Wiley

CVD Mortality Leading Cause of Death for Stage I, II Hodgkin Lymphoma – HealthDay

 


RCT | Enasidenib vs. conventional care in mutant-IDH2 relapsed/refractory acute myeloid leukemia.

22 Jul, 2022 | 11:31h | UTC

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial – Blood

 


The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends.

20 Jul, 2022 | 12:08h | UTC

The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends – The Lancet Haematology (free registration required)

 

Commentary on Twitter (thread – click for more)

 


Single-arm phase 2 study | Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.

20 Jul, 2022 | 11:37h | UTC

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

 


ELN International Recommendations for the diagnosis and management of acute myeloid leukemia in adults.

19 Jul, 2022 | 13:28h | UTC

Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel – Blood

 


Single arm phase 2 study | Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for hematopoietic stem cell transplantation.

19 Jul, 2022 | 13:00h | UTC

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma – MedPage Today (free registration required)

Related:

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Zanubrutinib vs. bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

19 Jul, 2022 | 12:57h | UTC

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Zanubrutinib Wins in First-Line CLL for Older Patients — The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial – MedPage Today (free registration required)

 


Stay Updated in Your Specialty

No spam, just news.